TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03566654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote ischemic conditioning
Description: RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeately for 5 times， two times per day. The duration of the treatment is 30+/-2days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ambulatory blood pressure monitoring
Description: A diagnostic technique for measuring blood pressure in daily life by means of automatic intermittent timing. Because ABPM has overcome the limitations of clinic blood pressure measurement, observation error and white coat effect, it can objectively reflect the actual level and fluctuation of blood pressure. Each patient of the two arms will use ABPM measure blood pressure before and after RIC or sham RIC treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ambulatory blood pressure monitoring
Description: A diagnostic technique for measuring blood pressure in daily life by means of automatic intermittent timing. Because ABPM has overcome the limitations of clinic blood pressure measurement, observation error and white coat effect, it can objectively reflect the actual level and fluctuation of blood pressure. Each patient of the two arms will use ABPM measure blood pressure before and after RIC or sham RIC treatment.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: Sham RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral arms and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeately for 5 times. The duration of the treatment is 30+/-2days.
Study: NCT03218345

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-guided RFA
Description: EUS-guided RFA would be performed using a 19-gauge RFA electrode and a generator
Study: NCT01545323

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: One 20cm2/10cm2 autologous skin sheet graft
Description: Adults will receive a graft of approximately 20cm2. Children under 16 years of age will receive a graft around half this size, around 10cm2 .The graft is derived from SPINK5 transduced cells
Study: NCT03390647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6130
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6130
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6130
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E6130-matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E6130-matched placebo
Study: NCT00371228

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delay of umbilical cord clamping
Description: Umbilical cord delayed until pulsation stops.
Study: NCT00851448

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral nutritional supplement, food for special medical purposes
Description: 2 servings of 200-300 ml per day, treatment period: 16 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: oral nutritional supplement, food for special medical purposes
Description: 2 servings of 200-300 ml per day, treatment period: 16 weeks
Study: NCT02729831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive decision aid
Description: The Healthwise Shared Decision Points in booklet version for hip and knee osteoarthritis

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive decision aid
Description: The Healthwise Shared Decision Points in booklet version for hip and knee osteoarthritis

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive decision aid
Description: The Healthwise Shared Decision Points in booklet version for hip and knee osteoarthritis

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video decision aid
Description: Health Dialog DVD and booklet decision aids for hip and knee osteoarthritis

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Report
Description: A short report that includes the patients' goals and treatment preferences

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Report
Description: A short report that includes the patients' goals and treatment preferences
Study: NCT00250939

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Myozyme
Description: 20 mg/kg qow
Study: NCT03751566

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Schedule of the acupuncture:~Acupuncture may be done ambulant or during hospitalisation . Acupuncture will be administered 1-3 times a week ( in case of severe toxicity and problems caused by the radiotherapy, it may continue also after the termination of the radiotherapy.) Acupuncture needles will be left for 5- 30 minutes, as per individual need of the patients.~Acupuncture will be performed by a physician trained in acupuncture.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard supportive therapy
Description: Standard supportive therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard supportive therapy
Description: Standard supportive therapy
Study: NCT03639467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib plus gemcitabine/cisplatin
Description: In the phase Ib portion, patients received dose escalation of anlotinb (from 8mg to 12mg orally once daily on days 1-14 of a 21-day) in combination with fixed dose of gemcitabine (1000mg/m2 intravenously on days 1 and 8) and cisplatin (80mg/m2 intravenously on day 1) every 3 weeks.~In the phase II portion, patients received anlotinb at recommended phase II dose determined in the phase Ib portion, in combination with fixed dose of gemcitabine and cisplatin every 3 weeks.~The combination of anlotinib plus gemcitabine / cisplatin was repeated every 3 weeks for up to six cycles. Patients with disease control (defined as a complete response, a partial response, or stable disease) continue to receive anlotinb until disease progression or unacceptable toxic effects, whichever occurred first.
Study: NCT02534298

Intervention type: OTHER
Group type: OTHER
Intervention: functional magnetic resonance imaging
Description: functional magnetic resonance imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional magnetic resonance imaging
Description: functional magnetic resonance imaging
Study: NCT03096704

Intervention type: DIAGNOSTIC_TEST
Intervention: vitamine d dosage
Description: dosage of vitamine D in slow transit time constipation
Study: NCT03505541

Intervention type: BIOLOGICAL
Intervention: Adiponectin and TNFa
Description: Adiponectin and TNFa are adipokines. Will be added to the myometrial biopsies to investigate their effect on the force of contractility

Intervention type: BIOLOGICAL
Intervention: Adiponectin and TNFa
Description: Adiponectin and TNFa are adipokines. Will be added to the myometrial biopsies to investigate their effect on the force of contractility

Intervention type: BIOLOGICAL
Intervention: Adiponectin and TNFa
Description: Adiponectin and TNFa are adipokines. Will be added to the myometrial biopsies to investigate their effect on the force of contractility
Study: NCT01103362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flibanserin
Description: all patients will receive open-label flibanserin 100mg
Study: NCT02033161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT
Description: The internet-treatment consisted of six modules during 8 weeks. Part 1: education about FGID and the treatment model. Part 2: individual symptom behavior. Part 3: toilet habits, or other common symptom behavior. Part 4 and Part 5: Exposure during 4 weeks. Part 6: relapse prevention.~Parents received four modules over 8 weeks consisting of psycho-education about FGID and the treatment model, increased positive time with the child in order to reduce attention to pain, parental symptom behavior, support child exposure and relapse prevention.~The therapists gave feedback weekly . All participants had at least 1 telephone call from their therapist during the fifth and sixth week of treatment.
Study: NCT01048671

Intervention type: DRUG
Intervention: Raltegravir
Description: Raltegravir was administered in combination with ARV therapies at the discretion of the investigator in accordance with the product label. The recommended dose of raltegravir is 400 mg twice daily.

Intervention type: DRUG
Intervention: ARV (non-raltegravir)
Description: ARV treatments were administered in combination with raltegravir at the discretion of the investigator in accordance with the product labels, and could include nucleoside reverse-transcriptase inhibitor, non-nucleoside reverse-transcriptase inhibitor, protease inhibitor, entry inhibitor, and integrase inhibitor catagories.
Study: NCT04619901

Intervention type: OTHER
Intervention: Semi-structured interviews
Description: Exploring the psychological and social impact on parents of a palliative care decision concerning their child in the neonatal period

Intervention type: OTHER
Intervention: Questionnaire
Description: Assessing the neuro-developmental evolution of children and understanding the determinants of the psychological and social impact of palliative care decisions on parents

Intervention type: OTHER
Intervention: Questionnaire
Description: Assessing the neuro-developmental evolution of children and understanding the determinants of the psychological and social impact of palliative care decisions on parents

Intervention type: OTHER
Intervention: following Scales
Description: Scales : Hospital Anxiety and Depression, Intolerance to Uncertainty, and Brief COPE.
Study: NCT04114630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erenumab 70mg/mL
Description: Unit dose: 70 mg/mL single-dose., prefilled erenumab autoinjectors. 140 mg dose = 2 x 70 mg/mL, single dose, prefilled erenumab autoinjectors
Study: NCT02567500

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patients with auditory hallucination
Description: Patients with auditory hallucination (20 for each arm):~Evaluation at time 0 and 6 month after of:~* The social cognitive marker (NEPSY II) : theory of mind and affect recognition~* The emotional marker:~  * Differential emotion scale IV (DES IV): emotional individual stability~ * Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.~* Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.~* Evaluation of diagnosis with DSM-IV criteria:~  * MINI-Kids~ * Psychosis section of Kiddie-SADS

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Patients without auditory hallucination
Description: Patients without auditory hallucination (20 for each arm):~Evaluation at time 0 and 6 month after of:~* The social cognitive marker (NEPSY II) : theory of mind and affect recognition~* The emotional marker:~  * Differential emotion scale IV (DES IV): emotional individual stability~ * Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.~* Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.~* Evaluation of diagnosis with DSM-IV criteria:~  * MINI-Kids~ * Psychosis section of Kiddie-SADS
Study: NCT04080921

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Description: Transplantation of Autologous Bone Marrow Mononuclear Cells
Study: NCT03481192

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Two visits for evaluation
Description: Visit 1:The first evaluation (E1) of cognitive functions will take place directly following the psychiatric interview (T1), in order to better reflect the cognitive abilities at the time of the proposal of the care project.~This will include the Memory Functioning Questionnaire (MFQ), the five words of DUBOIS, the TMT-A and B, the WAIS code test, and the BADDELEY door test. An intercurrent type ringing event of the phone will take place during this evaluation.~Visit 2: At 24h-48h of the psychiatric evaluation (T2), a second evaluation (E2) will take place.~An episodic memory score will be determined by asking the patient to recall,as precisely as possible the evaluation E1. At first the reminder will be free,the data can be completed, if necessary, with an indication, a recognition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two visits for evaluation
Description: Visit 1:The first evaluation (E1) of cognitive functions will take place directly following the psychiatric interview (T1), in order to better reflect the cognitive abilities at the time of the proposal of the care project.~This will include the Memory Functioning Questionnaire (MFQ), the five words of DUBOIS, the TMT-A and B, the WAIS code test, and the BADDELEY door test. An intercurrent type ringing event of the phone will take place during this evaluation.~Visit 2: At 24h-48h of the psychiatric evaluation (T2), a second evaluation (E2) will take place.~An episodic memory score will be determined by asking the patient to recall,as precisely as possible the evaluation E1. At first the reminder will be free,the data can be completed, if necessary, with an indication, a recognition.
Study: NCT02536807

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hyaluronan
Description: HA gel injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronan
Description: HA gel injection
Study: NCT03060668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peptamen intense
Description: Study group will receive a nutritional formula containing 1.0 kcal/ml and 93 g/L of protein

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Novasource senior
Description: Control group will receive a nutritional formula containing 1.2 kcal/ml and 65 g/L of protein
Study: NCT02277002

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cabin Air Filtration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No Cabin Air Filtration
Study: NCT02901782

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Personalized titanium plate
Description: 3D models of tumor-bearing bone segments were constructed by using computed tomography (CT) and magnetic resonance imaging (MRI). The 3D models were used to design the model of personalized titanium plates. The model of the plates was transferred into a numerical control machine for manufacturing the personalized titanium plates by 3D printing technology. The plates were then surgically implanted for reconstruction assistance following microwave-induced hyperthermia to remove the bone tumor. Implementation parameters and knee function were then evaluated.
Study: NCT02482337

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POEM
Description: POEM procedure in the OR
Study: NCT03009760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 50mg(HP-)
Description: CJ-12420 50mg in H. pylori negative subject

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 100mg(HP-)
Description: CJ-12420 100mg in H. pylori negative subject

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 50mg(HP+)
Description: CJ-12420 50mg in H. pylori positive subject

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 100mg(HP+)
Description: CJ-12420 100mg in H. pylori positive subject
Study: NCT03715439

Intervention type: DEVICE
Intervention: Dental implant
Description: A single dental implant was inserted 3 months after tooth extraction

Intervention type: DEVICE
Intervention: Dental implant
Description: A single dental implant was inserted 3 months after tooth extraction
Study: NCT03587077

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: vaginal application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: vaginal application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: vaginal application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isosorbide mononitrate
Description: vaginal application
Study: NCT01097382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZOLPIDEM
Description: Pharmaceutical form: tablet Route of administration: oral Dose regimen: once daily
Study: NCT00617474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: sub cutaneous injection, 2000 unit in per injection, 3 times 1 week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT00407277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: 21 mg of nicotine via a dermal patch

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo via a dermal patch

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation group therapy
Description: a 9-week group based on the Freedom From Smoking program designed by the American Lung Association. The treatment was manualized and modified to meet the functional and cognitive capabilities of patients with psychotic disorders
Study: NCT04612374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Description: Please see arm/group descriptions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Description: Please see arm/group descriptions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Revised Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Description: Please see arm/group descriptions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Revised Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Description: Please see arm/group descriptions
Study: NCT02810548

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD alone
Description: Periodontal surgical cleaning procedure

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: OFD alone
Description: Periodontal surgical cleaning procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD alone
Description: Periodontal surgical cleaning procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD alone
Description: Periodontal surgical cleaning procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich Fibrin
Description: Natural platelet concentrate rich in growth factors

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich Fibrin
Description: Natural platelet concentrate rich in growth factors

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nanohydroxyapatite
Description: Synthetic bone graft

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nanohydroxyapatite
Description: Synthetic bone graft
Study: NCT01303731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine and Fentanyl
Description: Spinal anesthesia with Marcaine Spinal 0.5% Heavy 7.5 mg (1.5 ml) diluted in 0.75ml of patient's CSF (0.25 ml)with addition of Fentanyl 12.5 mcg (total 2.5 ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Spinal anesthesia with Marcaine Spinal 0.5% Heavy 12.5 mg (2.5 ml)
Study: NCT03676231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGM-1019
Description: Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGM-1019
Description: Active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive
Study: NCT00857272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG electrolyte lavage solution + bisacodyl - reformulation
Description: multi dose formulation (tablet/solution) for oral administration prior to colonoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG electrolyte lavage solution + bisacodyl
Description: multi dose preparation (tablet/solution) for oral administration prior to colonoscopy
Study: NCT02504944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol 0.2% eye drops
Description: Enrolled preterm newborns will receive propranolol as ophthalmic solution (0.2%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, four times daily (every 6 hours). Propranolol treatment will be always associated to the conventional approach adopted by the Early Treatment for Retinopathy of Prematurity Study (ETROP) Cooperative Group.
Study: NCT03058146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Health Walking Condition
Description: Physically inactive older adults in this condition will perform 3 months of prescribed brisk walking (to increase cardio respiratory fitness) in their real world environments, using mobile health (mHealth) devices during each exercise session to achieve and maintain a minimum of 150 minutes of moderate to vigorous physical activity (MVPA) per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Aging Education Condition
Description: The education control condition will provide participants with printed materials and homework assignments on issues related to successful aging, such as nutrition, social activity, cognitive and social engagement.
Study: NCT01706133

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Factors associated with the use of emergency departments
Description: Participants who were assigned to the intervention will be evaluated jointly by the medical service by a medical specialist in geriatrics and a nurse trained in gerontology and geriatrics. The doctor will monitor the apparition and / or aggravation of any geriatric syndromes already established by the specialty in geriatrics, namely, polypharmacy, delirium, dementia, depression, risk of falls, etc.. The nurse will monitor and follow up in four areas I. medical issues (pressure ulcers, infusion, mobility); II. Mental and emotional state and coping strategies with hospitalization; III. functionality, and IV. Atmosphere (A. Service status, architectural difficulties for mobility, bathing etc. B. Support Network, caregiver, and C. hardship)
Study: NCT02293694

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sayana Press
Description: Sayana® Press is a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) in a prefilled, auto-disabled injection system called Uniject

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sayana Press
Description: Sayana® Press is a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) in a prefilled, auto-disabled injection system called Uniject
Study: NCT00728585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Given IV

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given IV